JP2016509582A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016509582A5 JP2016509582A5 JP2015549737A JP2015549737A JP2016509582A5 JP 2016509582 A5 JP2016509582 A5 JP 2016509582A5 JP 2015549737 A JP2015549737 A JP 2015549737A JP 2015549737 A JP2015549737 A JP 2015549737A JP 2016509582 A5 JP2016509582 A5 JP 2016509582A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- human
- molecule
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 90
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 64
- 206010028980 Neoplasm Diseases 0.000 claims description 54
- 210000004027 cell Anatomy 0.000 claims description 44
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims description 32
- 102000055298 human VTCN1 Human genes 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 31
- 201000011510 cancer Diseases 0.000 claims description 28
- 210000004981 tumor-associated macrophage Anatomy 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 208000035473 Communicable disease Diseases 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 16
- 230000001404 mediated effect Effects 0.000 claims description 16
- 210000004881 tumor cell Anatomy 0.000 claims description 16
- 230000001629 suppression Effects 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 239000002246 antineoplastic agent Substances 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 238000003556 assay Methods 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 230000002380 cytological effect Effects 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 230000001747 exhibiting effect Effects 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 8
- 230000001684 chronic effect Effects 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 5
- 230000002147 killing effect Effects 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 206010062016 Immunosuppression Diseases 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 4
- 238000001815 biotherapy Methods 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 238000001794 hormone therapy Methods 0.000 claims description 4
- 230000028993 immune response Effects 0.000 claims description 4
- 230000001506 immunosuppresive effect Effects 0.000 claims description 4
- 238000009169 immunotherapy Methods 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 230000005909 tumor killing Effects 0.000 claims description 4
- 230000034994 death Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 claims description 2
- 238000003364 immunohistochemistry Methods 0.000 claims description 2
- 210000004882 non-tumor cell Anatomy 0.000 claims description 2
- 230000006037 cell lysis Effects 0.000 claims 2
- 238000011394 anticancer treatment Methods 0.000 claims 1
- 206010057248 Cell death Diseases 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261739272P | 2012-12-19 | 2012-12-19 | |
| US201261739287P | 2012-12-19 | 2012-12-19 | |
| US201261739353P | 2012-12-19 | 2012-12-19 | |
| US61/739,353 | 2012-12-19 | ||
| US61/739,272 | 2012-12-19 | ||
| US61/739,287 | 2012-12-19 | ||
| PCT/US2013/076701 WO2014100483A1 (en) | 2012-12-19 | 2013-12-19 | Anti-human b7-h4 antibodies and their uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016509582A JP2016509582A (ja) | 2016-03-31 |
| JP2016509582A5 true JP2016509582A5 (OSRAM) | 2017-01-19 |
Family
ID=49917300
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549737A Pending JP2016509582A (ja) | 2012-12-19 | 2013-12-19 | 抗ヒトｂ７−ｈ４抗体およびその使用 |
| JP2015549721A Pending JP2016505843A (ja) | 2012-12-19 | 2013-12-19 | Ｂ７−ｈ４特異的抗体、並びにその組成物及び使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549721A Pending JP2016505843A (ja) | 2012-12-19 | 2013-12-19 | Ｂ７−ｈ４特異的抗体、並びにその組成物及び使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9574000B2 (OSRAM) |
| EP (2) | EP2934575A2 (OSRAM) |
| JP (2) | JP2016509582A (OSRAM) |
| KR (1) | KR20150100716A (OSRAM) |
| CN (1) | CN104955475A (OSRAM) |
| AU (2) | AU2013361231A1 (OSRAM) |
| BR (1) | BR112015014063A2 (OSRAM) |
| CA (2) | CA2894689A1 (OSRAM) |
| HK (1) | HK1210027A1 (OSRAM) |
| MX (1) | MX2015007846A (OSRAM) |
| RU (1) | RU2015129551A (OSRAM) |
| SG (1) | SG11201504764SA (OSRAM) |
| WO (2) | WO2014100483A1 (OSRAM) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012145568A1 (en) | 2011-04-21 | 2012-10-26 | Albert Einstein College Of Medicine Of Yeshiva University | Antibodies to human b7x for treatment of metastatic cancer |
| CA2845536A1 (en) * | 2011-08-15 | 2013-02-21 | Amplimmune, Inc. | Anti-b7-h4 antibodies and their uses |
| EP2773651B1 (en) | 2011-11-03 | 2020-12-23 | The Trustees of the University of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
| AU2014244424A1 (en) | 2013-03-14 | 2015-08-27 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| ITMI20130692A1 (it) | 2013-04-26 | 2014-10-27 | Copan Italia Spa | Dispositivo e procedimento per il processamento automatico di piastre di coltura per campioni microbiologici |
| HRP20201906T1 (hr) | 2013-12-20 | 2021-04-02 | Fred Hutchinson Cancer Research Center | Označene kimerne efektorske molekule i njihovi receptori |
| CN113698485A (zh) * | 2014-09-12 | 2021-11-26 | 基因泰克公司 | 抗-b7-h4抗体及免疫缀合物 |
| CN106999585A (zh) * | 2014-09-28 | 2017-08-01 | 加利福尼亚大学董事会 | 对刺激性和非刺激性骨髓细胞的调节 |
| WO2016070001A1 (en) * | 2014-10-31 | 2016-05-06 | Jounce Therapeutics, Inc. | Methods of treating conditions with antibodies that bind b7-h4 |
| MX2017011644A (es) | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos. |
| JP2018518151A (ja) * | 2015-03-27 | 2018-07-12 | ユニバーシティ オブ サザン カリフォルニア | Ｂ７−ｈ４発現充実性腫瘍を処置するためのｃａｒ ｔ細胞 |
| WO2016176652A2 (en) | 2015-04-29 | 2016-11-03 | Fred Hutchinson Cancer Research Center | Modified stem cells and uses thereof |
| AU2016257929B2 (en) | 2015-05-04 | 2022-10-20 | Cytomx Therapeutics, Inc | Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof |
| SI3370768T1 (sl) | 2015-11-03 | 2022-04-29 | Janssen Biotech, Inc. | Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe |
| SG10201601719RA (en) | 2016-03-04 | 2017-10-30 | Agency Science Tech & Res | Anti-LAG-3 Antibodies |
| SG10201603721TA (en) | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
| KR102346988B1 (ko) | 2016-07-26 | 2022-01-03 | 시즈오카켄 | 항 b7-h4 항체 |
| WO2018058002A1 (en) | 2016-09-23 | 2018-03-29 | Fred Hutchinson Cancer Research Center | Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof |
| BR112019018863A8 (pt) | 2017-03-15 | 2023-05-02 | Hutchinson Fred Cancer Res | Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos |
| US11932694B2 (en) | 2017-04-19 | 2024-03-19 | Bluefin Biomedicine, Inc. | Anti-VTCN1 antibodies and antibody drug conjugates |
| KR102641269B1 (ko) | 2017-05-24 | 2024-02-26 | 이펙터 테라퓨틱스, 인크. | 개선된 항종양 면역 반응을 위한 조성물 및 방법 |
| EP3630838A1 (en) | 2017-06-01 | 2020-04-08 | CytomX Therapeutics, Inc. | Activatable anti-pdl1 antibodies, and methods of use thereof |
| US10814011B1 (en) | 2017-06-16 | 2020-10-27 | Nantbio, Inc. | Anti-B7-H4 antibodies and methods |
| US11220544B2 (en) * | 2017-07-14 | 2022-01-11 | Cytomx Therapeutics, Inc. | Anti-CD166 antibodies and uses thereof |
| EP3652749A4 (en) | 2017-07-14 | 2021-03-24 | The Regents of The University of California | NEW PROCESSES FOR PREDICTING THE RISK OF GRAFT REJECTION |
| MX2020001287A (es) | 2017-08-11 | 2020-08-20 | Hutchinson Fred Cancer Res | Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos. |
| UA128472C2 (uk) | 2017-08-25 | 2024-07-24 | Файв Прайм Терапеутікс Інк. | B7-h4 антитіла і методи їх використання |
| US20200262894A1 (en) | 2017-09-06 | 2020-08-20 | Fred Hutchinson Cancer Research Center | Strep-tag specific binding proteins and uses thereof |
| CN111065410A (zh) | 2017-09-06 | 2020-04-24 | 弗雷德哈钦森癌症研究中心 | 用于改善过继细胞疗法的方法 |
| WO2019051128A1 (en) | 2017-09-06 | 2019-03-14 | Fred Hutchinson Cancer Research Center | SPECIFIC STREP LABEL CHIMERIC RECEPTORS AND USES THEREOF |
| EP3697435A1 (en) | 2017-10-20 | 2020-08-26 | Fred Hutchinson Cancer Research Center | Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression |
| WO2019109047A1 (en) | 2017-12-01 | 2019-06-06 | Fred Hutchinson Cancer Research Center | Binding proteins specific for 5t4 and uses thereof |
| WO2019140278A1 (en) | 2018-01-11 | 2019-07-18 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting core binding factor antigens |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| KR20200112913A (ko) * | 2018-01-23 | 2020-10-05 | 넥스트큐어 인코포레이티드 | B7-h4 항체 및 그 사용 방법 |
| CN110366560B (zh) * | 2018-02-11 | 2023-07-28 | 江苏豪森药业集团有限公司 | 抗b7-h4抗体、其抗原结合片段及其医药用途 |
| CA3090700A1 (en) | 2018-02-12 | 2019-08-15 | Fred Hutchinson Cancer Research Center | Cyclin a1 specific t cell receptors and uses thereof |
| CN111868089B (zh) * | 2018-02-21 | 2025-08-22 | 戊瑞治疗有限公司 | B7-h4抗体给药方案 |
| BR112020016986A2 (pt) | 2018-02-21 | 2021-03-02 | Five Prime Therapeutics, Inc. | formulações de anticorpo contra b7-h4 |
| CA3091138A1 (en) | 2018-02-26 | 2019-08-29 | Fred Hutchinson Cancer Research Center | Compositions and methods for cellular immunotherapy |
| CA3091801A1 (en) * | 2018-03-02 | 2019-09-06 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
| US20210221894A1 (en) * | 2018-04-03 | 2021-07-22 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and an antigen associated with tumors, mdscs and/or tams |
| US11440967B2 (en) | 2018-05-31 | 2022-09-13 | Glyconex Inc. | Therapeutic antibodies |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
| JP2021534752A (ja) | 2018-08-22 | 2021-12-16 | フレッド ハッチンソン キャンサー リサーチ センター | Ｋｒａｓ抗原またはｈｅｒ２抗原を標的とする免疫療法 |
| WO2020068702A1 (en) | 2018-09-24 | 2020-04-02 | Fred Hutchinson Cancer Research Center | Chimeric receptor proteins and uses thereof |
| WO2020097530A2 (en) | 2018-11-09 | 2020-05-14 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting mesothelin |
| US12304946B2 (en) | 2018-12-19 | 2025-05-20 | Humabs Biomed Sa | Antibodies that neutralize hepatitis B virus and uses thereof |
| WO2020140070A1 (en) * | 2018-12-27 | 2020-07-02 | Gigagen, Inc. | Anti-b7-h4 binding proteins and methods of use thereof |
| GB2596461B (en) | 2019-02-20 | 2023-09-27 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
| US12448430B2 (en) | 2019-03-11 | 2025-10-21 | Fred Hutchinson Cancer Center | High avidity WT1 T cell receptors and uses thereof |
| WO2020187327A1 (en) * | 2019-03-21 | 2020-09-24 | Suzhou Kanova Biopharmaceutical Co. Ltd. | Anti-b7s1 polypeptides and their use |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| EP4017872A1 (en) | 2019-08-20 | 2022-06-29 | Fred Hutchinson Cancer Center | T-cell immunotherapy specific for wt-1 |
| NZ785788A (en) | 2019-08-29 | 2025-09-26 | Vir Biotechnology Inc | Antibody compositions and methods for treating hepatitis b virus infection |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| CN115643806A (zh) * | 2020-01-31 | 2023-01-24 | 璟尚生物制药公司 | 双特异性t细胞接合器 |
| AR122722A1 (es) | 2020-06-24 | 2022-09-28 | Vir Biotechnology Inc | Anticuerpos que neutralizan el virus de la hepatitis b y sus usos |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| EP4155320A4 (en) * | 2020-06-30 | 2024-03-27 | Nona Biosciences (Suzhou) Co., Ltd. | ANTI-B7H4 ANTIBODIES AND BISPECIFIC ANTIBODIES AND USE THEREOF |
| US20240383983A1 (en) | 2020-08-18 | 2024-11-21 | Abl Bio, Inc. | Anti-B7-H4/Anti-4-1BB Bispecific Antibodies And Use Thereof |
| WO2022066973A1 (en) | 2020-09-24 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting pbk or oip5 antigens |
| WO2022066965A2 (en) | 2020-09-24 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting sox2 antigens |
| TW202222841A (zh) | 2020-10-06 | 2022-06-16 | 福瑞德哈金森腫瘤研究中心 | 用於治療表現mage-a1之疾病的組成物及方法 |
| WO2022132836A2 (en) | 2020-12-14 | 2022-06-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for cellular immunotherapy |
| KR20230137339A (ko) | 2021-01-04 | 2023-10-04 | 메르사나 테라퓨틱스, 인코포레이티드 | B7h4-표적화된 항체-약물 접합체 및 이의 사용 방법 |
| US20240092872A1 (en) | 2021-01-26 | 2024-03-21 | Vir Biotechnology, Inc. | Compositions and methods for treating hepatitis b virus infection |
| US20240199750A1 (en) | 2021-03-26 | 2024-06-20 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
| CA3214085A1 (en) | 2021-03-31 | 2022-10-06 | Darby Rye Schmidt | Thanotransmission polypeptides and their use in treating cancer |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| KR20240019297A (ko) | 2021-06-09 | 2024-02-14 | 이나뜨 파르마 에스.에이. | Nkp46, 사이토카인 수용체, 종양 항원 및 cd16a 에 결합하는 다중특이적 단백질 |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| KR20240026507A (ko) | 2021-06-29 | 2024-02-28 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도 |
| WO2023288281A2 (en) | 2021-07-15 | 2023-01-19 | Fred Hutchinson Cancer Center | Chimeric polypeptides |
| IL313159A (en) | 2021-12-01 | 2024-07-01 | Kadmon Corp Llc | B7-H4 antibodies and ANTI-B7-H4 antibody/IL-15 fusion proteins |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| AR129399A1 (es) | 2022-05-23 | 2024-08-21 | Vir Biotechnology Inc | Anticuerpos diseñados neutralizantes del virus de la hepatitis b y usos de los mismos |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| KR20250129802A (ko) | 2023-01-09 | 2025-08-29 | 프로타라 쎄라퓨틱스 인코포레이티드 | 삼중 음성 유방암 및 비-근육 침습성 방광암 치료를 위한 Streptococcus pyogenes의 비생존 세포와 면역 관문 억제제의 조합 |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| WO2024208818A1 (en) | 2023-04-04 | 2024-10-10 | Innate Pharma | Modular chimeric antigen receptor |
| WO2025081123A1 (en) | 2023-10-12 | 2025-04-17 | Fred Hutchinson Cancer Center | Methods and compositions for improving t cell immunotherapy |
| WO2025101820A1 (en) | 2023-11-08 | 2025-05-15 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| WO2025245169A1 (en) | 2024-05-21 | 2025-11-27 | Fred Hutchinson Cancer Center | Immunotherapy cells equipped with a collagen-targeting payload |
Family Cites Families (141)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| ATE37983T1 (de) | 1982-04-22 | 1988-11-15 | Ici Plc | Mittel mit verzoegerter freigabe. |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| WO1989007142A1 (en) | 1988-02-05 | 1989-08-10 | Morrison Sherie L | Domain-modified constant region antibodies |
| GB8808015D0 (en) | 1988-04-06 | 1988-05-05 | Ritter M A | Chemical compounds |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US20040049014A1 (en) | 1988-12-28 | 2004-03-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
| WO1991005548A1 (en) | 1989-10-10 | 1991-05-02 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| AU642932B2 (en) | 1989-11-06 | 1993-11-04 | Alkermes Controlled Therapeutics, Inc. | Protein microspheres and methods of using them |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| JPH06507404A (ja) | 1991-05-01 | 1994-08-25 | ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン | 感染性の呼吸性疾患の治療方法 |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5120727A (en) | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Rapamycin dimers |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US6787153B1 (en) | 1991-06-28 | 2004-09-07 | Mitsubishi Chemical Corporation | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane |
| US5202332A (en) | 1991-08-07 | 1993-04-13 | American Home Products Corporation | Rapamycin analog as immunosuppressant |
| US5162333A (en) | 1991-09-11 | 1992-11-10 | American Home Products Corporation | Aminodiesters of rapamycin |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| DE69233204T2 (de) | 1991-12-13 | 2004-07-15 | Xoma Corp., Berkeley | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| NZ251628A (en) | 1992-03-30 | 1996-07-26 | American Home Prod | Aqueous insectable rapamycin solution; product containing concentrate and diluent solutions |
| EP0656946B2 (en) | 1992-08-21 | 2010-03-31 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| CH686365A5 (de) | 1992-10-06 | 1996-03-15 | Werner Hofliger | Mobilkran. |
| US5434260A (en) | 1992-10-13 | 1995-07-18 | American Home Products Corporation | Carbamates of rapamycin |
| US5489680A (en) | 1992-10-13 | 1996-02-06 | American Home Products Corporation | Carbamates of rapamycin |
| US5441050A (en) | 1992-12-18 | 1995-08-15 | Neoprobe Corporation | Radiation responsive surgical instrument |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| DE69427974T2 (de) | 1993-04-29 | 2001-12-06 | Unilever N.V., Rotterdam | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| US5387680A (en) | 1993-08-10 | 1995-02-07 | American Home Products Corporation | C-22 ring stabilized rapamycin derivatives |
| US5385908A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
| SG64372A1 (en) | 1993-12-17 | 1999-04-27 | Novartis Ag | Rapamycin derivatives |
| US5362735A (en) | 1994-02-23 | 1994-11-08 | Smithkline Beecham Corporation | Rapamycin derivatives |
| EP0805678B1 (en) | 1995-01-05 | 2003-10-29 | THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN | Surface-modified nanoparticles and method of making and using same |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| AU710347B2 (en) | 1995-08-31 | 1999-09-16 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US5780462A (en) | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
| US5942328A (en) | 1996-02-29 | 1999-08-24 | International Business Machines Corporation | Low dielectric constant amorphous fluorinated carbon and method of preparation |
| ATE508733T1 (de) | 1996-03-04 | 2011-05-15 | Penn State Res Found | Materialien und verfahren zur steigerung der zellulären internalisierung |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| WO1998031346A1 (en) | 1997-01-16 | 1998-07-23 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US5989591A (en) | 1997-03-14 | 1999-11-23 | American Home Products Corporation | Rapamycin formulations for oral administration |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| US5843597A (en) | 1997-12-01 | 1998-12-01 | Eveready Battery Company, Inc. | Ribbed gasket for miniature galvanic cell |
| US6982323B1 (en) | 1997-12-23 | 2006-01-03 | Alexion Pharmaceuticals, Inc. | Chimeric proteins for diagnosis and treatment of diabetes |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| CA2336139C (en) | 1998-06-24 | 2008-10-14 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| GB9814640D0 (en) | 1998-07-06 | 1998-09-02 | Fujisawa Pharmaceutical Co | New use |
| US6015809A (en) | 1998-08-17 | 2000-01-18 | American Home Products Corporation | Photocyclized rapamycin |
| CA2341142A1 (en) | 1998-09-02 | 2000-03-09 | Diadexus Llc | A novel method of diagnosing, monitoring, staging, imaging and treating various cancers |
| US6311415B1 (en) | 1998-09-14 | 2001-11-06 | Lind Shoe Company | Bowling shoe with replaceable tip |
| US7888477B2 (en) | 1998-12-17 | 2011-02-15 | Corixa Corporation | Ovarian cancer-associated antibodies and kits |
| US6962980B2 (en) | 1999-09-24 | 2005-11-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| WO2002010187A1 (en) | 2000-07-27 | 2002-02-07 | Mayo Foundation For Medical Education And Research | B7-h3 and b7-h4, novel immunoregulatory molecules |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| FR2844455B1 (fr) | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
| FR2844513B1 (fr) | 2002-09-13 | 2007-08-03 | Lab Francais Du Fractionnement | Anticorps pour adcc et induisant la production de cytokines. |
| CA2499816C (en) | 2002-09-27 | 2013-07-30 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| EP1587540B1 (en) | 2003-01-09 | 2021-09-15 | MacroGenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
| WO2004073656A2 (en) | 2003-02-20 | 2004-09-02 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| PL1608400T3 (pl) | 2003-03-28 | 2010-11-30 | Faron Pharmaceuticals Oy | Podwyższanie poziomu adenozyny przez indukowaną przez cytokiny ekspresję CD73 |
| CA2525899C (en) | 2003-05-09 | 2016-03-08 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
| US20050208627A1 (en) | 2003-09-18 | 2005-09-22 | Bowdish Katherine S | Elicitation of antibodies to self peptides in mice by immunization with dendritic cells |
| JP2008504821A (ja) | 2004-07-01 | 2008-02-21 | バイレクシス コーポレイション | ベクター・パッケージング細胞系列 |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| ATE462726T1 (de) * | 2005-01-07 | 2010-04-15 | Diadexus Inc | Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür |
| WO2006117910A1 (ja) * | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
| WO2006121991A2 (en) | 2005-05-06 | 2006-11-16 | Diadexus, Inc. | Compositions and methods for detection, prognosis and treatment of breast cancer |
| EP3130350A1 (en) | 2005-06-08 | 2017-02-15 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway |
| CA2612355A1 (en) | 2005-06-16 | 2006-12-28 | Virxsys Corporation | Antibody complexes |
| JP2006345852A (ja) | 2005-06-16 | 2006-12-28 | Virxsys Corp | 抗体複合体 |
| WO2007041694A2 (en) | 2005-10-04 | 2007-04-12 | The Johns Hopkins University | Compositions and methods for treating inflammation |
| CA2630483C (en) * | 2005-12-08 | 2015-05-19 | Medarex, Inc. | Human monoclonal antibodies to o8e |
| MX2008007292A (es) | 2005-12-08 | 2008-10-17 | Univ Louisville Res Found | Composiciones inmunoestimuladoras y metodos. |
| US20070160578A1 (en) | 2005-12-14 | 2007-07-12 | The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services | Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes |
| US20090215084A1 (en) | 2006-01-05 | 2009-08-27 | Mayo Foundation For Medical Education And Research | B7-h1 and b7-h4 in cancer |
| US20100028450A1 (en) | 2006-01-25 | 2010-02-04 | The Board Of Trustees Of The University Of Illinoi S | Tolerogenic biodegradable artificial antigen presenting system |
| US7951918B2 (en) | 2006-03-17 | 2011-05-31 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| US9121853B2 (en) | 2006-03-20 | 2015-09-01 | Mayo Foundation For Medical Education And Research | B7-H4 expression on tumor vasculature |
| CA2639070A1 (en) | 2006-04-13 | 2007-11-01 | Oncomethylime Sciences S.A. | Novel tumour suppressor |
| WO2007124361A2 (en) | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
| CA2673659A1 (en) | 2006-12-27 | 2008-07-10 | The Johns Hopkins University | Methods of detecting and diagnosing inflamatory responses and disorders by determining the level of soluble b7-h4 |
| US20090142342A1 (en) | 2006-12-27 | 2009-06-04 | Johns Hopkins University | B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases |
| US7989173B2 (en) * | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
| AU2008207735B2 (en) | 2007-01-26 | 2013-10-03 | University Of Louisville Research Foundation, Inc. | Modification of exosomal components for use as a vaccine |
| EP2111231A4 (en) | 2007-02-13 | 2010-12-15 | Univ Northeastern | METHOD AND COMPOSITIONS FOR IMPROVING IMMUNE REACTIONS |
| TW200938224A (en) * | 2007-11-30 | 2009-09-16 | Medarex Inc | Anti-B7H4 monoclonal antibody-drug conjugate and methods of use |
| WO2009111315A2 (en) | 2008-02-29 | 2009-09-11 | Mayo Foundation For Medical Education And Research | Methods for reducing granulomatous inflammation |
| WO2010102167A1 (en) | 2009-03-05 | 2010-09-10 | Becton, Dickinson And Company | Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer |
| AU2010221188A1 (en) | 2009-03-06 | 2011-10-20 | Tripath Imaging, Inc. | Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer |
| US8445207B2 (en) | 2009-04-07 | 2013-05-21 | Korea Institute Of Science And Technology | Genes based on thalidomide, valproic acid and methotrexate treatment for screening of drug inducing teratogenicity and screening method using thereof |
| US20130209514A1 (en) | 2009-06-09 | 2013-08-15 | Eli Gilboa | Aptamer-targeted costimulatory ligand aptamer |
| EP2445538A2 (en) | 2009-06-23 | 2012-05-02 | University Of Miami | Aptamer-targeted sirna to inhibit nonsense mediated decay |
| JP5769316B2 (ja) * | 2009-08-06 | 2015-08-26 | イムナス・ファーマ株式会社 | Ａβオリゴマーに特異的に結合する抗体およびその利用 |
| US9005616B2 (en) | 2009-08-31 | 2015-04-14 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
| PL2699264T3 (pl) * | 2011-04-20 | 2018-08-31 | Medimmune, Llc | Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1 |
| CA2845536A1 (en) | 2011-08-15 | 2013-02-21 | Amplimmune, Inc. | Anti-b7-h4 antibodies and their uses |
-
2013
- 2013-12-19 EP EP13815940.5A patent/EP2934575A2/en not_active Withdrawn
- 2013-12-19 BR BR112015014063A patent/BR112015014063A2/pt not_active IP Right Cessation
- 2013-12-19 KR KR1020157017826A patent/KR20150100716A/ko not_active Withdrawn
- 2013-12-19 AU AU2013361231A patent/AU2013361231A1/en not_active Abandoned
- 2013-12-19 RU RU2015129551A patent/RU2015129551A/ru not_active Application Discontinuation
- 2013-12-19 JP JP2015549737A patent/JP2016509582A/ja active Pending
- 2013-12-19 HK HK15110787.9A patent/HK1210027A1/xx unknown
- 2013-12-19 CA CA2894689A patent/CA2894689A1/en not_active Abandoned
- 2013-12-19 CN CN201380066946.1A patent/CN104955475A/zh active Pending
- 2013-12-19 MX MX2015007846A patent/MX2015007846A/es unknown
- 2013-12-19 EP EP13818155.7A patent/EP2934576A1/en not_active Withdrawn
- 2013-12-19 US US14/654,074 patent/US9574000B2/en not_active Expired - Fee Related
- 2013-12-19 WO PCT/US2013/076701 patent/WO2014100483A1/en not_active Ceased
- 2013-12-19 CA CA2894879A patent/CA2894879A1/en not_active Abandoned
- 2013-12-19 AU AU2013361275A patent/AU2013361275B2/en not_active Ceased
- 2013-12-19 JP JP2015549721A patent/JP2016505843A/ja active Pending
- 2013-12-19 WO PCT/US2013/076619 patent/WO2014100439A2/en not_active Ceased
- 2013-12-19 SG SG11201504764SA patent/SG11201504764SA/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016509582A5 (OSRAM) | ||
| RU2015129551A (ru) | Антитела к в7-н4 человека и их применение | |
| Bacac et al. | CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies | |
| KR102349056B1 (ko) | Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법 | |
| Lopez-Albaitero et al. | Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody | |
| US10633450B2 (en) | Methods for enhancing anti-tumor antibody therapy | |
| JP2023129543A (ja) | 抗ｃｄ７３抗体およびそれらの使用方法 | |
| JP2014531409A5 (OSRAM) | ||
| ES2951650T3 (es) | Uso de un anticuerpo anti-PD-1 junto con un anticuerpo anti-CD30 en el tratamiento del linfoma | |
| RU2018107047A (ru) | Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения | |
| JP7453971B2 (ja) | Ｎｋエンゲージャー分子およびその使用方法 | |
| JP2016520082A5 (OSRAM) | ||
| JP2016509585A5 (OSRAM) | ||
| JP2020524149A5 (OSRAM) | ||
| JP2016538297A5 (OSRAM) | ||
| US20230406918A1 (en) | Method of treatment of a tumor with il-8 antibody | |
| JP2019510769A (ja) | チェックポイント阻害剤と組み合わされた腫瘍溶解性ウイルスによるがん療法 | |
| US20250043023A1 (en) | Targeting moiety-drug grafted immune cell compositions and methods of use | |
| Sun et al. | Leveraging T cell co-stimulation for enhanced therapeutic efficacy of trispecific antibodies targeting prostate cancer | |
| Karizak et al. | Understanding the regulation of “Don’t Eat-Me” signals by inflammatory signaling pathways in the tumor microenvironment for more effective therapy | |
| US20240374644A1 (en) | Herv-k antibody therapeutics | |
| Ploeg | Novel approaches towards cancer-directed immune checkpoint inhibition | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| Gross et al. | CD19× CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease | |
| Zhang | Cancer Immunotherapy |